Canada Markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.97+0.43 (+2.00%)
At close: 04:00PM EDT
21.97 -0.03 (-0.14%)
After hours: 04:03PM EDT

Myriad Genetics, Inc.

320 Wakara Way
Salt Lake City, UT 84108
United States
801 584 3600
https://myriad.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees2,400

Key Executives

NameTitlePayExercisedYear Born
Mr. Paul J. DiazCEO, Pres & Director2.92MN/A1962
Mr. R. Bryan RiggsbeeExec. VP, CFO & Treasurer934.49kN/A1971
Ms. Nicole LambertCOO & Pres of Myriad Genetic Laboratories825.23kN/A1974
Mr. Mark S. VerrattiChief Commercial Officer723.29kN/A1968
Dr. Kevin Richard HaasChief Technology OfficerN/AN/A1986
Dr. Dale Muzzey Ph.D.Chief Scientific OfficerN/AN/A1980
Mr. Scott GleasonSr. VP of Investor RelationsN/AN/A1979
Mr. Nathan SmithSr. VP of Investor Relations & TreasuryN/AN/AN/A
Dr. Clivetty MartinezChief Compliance OfficerN/AN/AN/A
Ms. Pamela WongChief Legal OfficerN/AN/A1968
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Corporate Governance

Myriad Genetics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 5. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 6; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.